MetaCap

Lipocine Insider Trades

NASDAQ: LPCNHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.72-0.21 (-10.88%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

Last 12 months

Purchases
7 · $516.77K
Sales
0 · $0
Shares bought / sold
250.57K / 0
Net activity
Net buying $516,774

Lipocine insider activity

Over the last 12 months, Lipocine insiders reported 7 transactions on SEC Form 4: 7 open-market purchases and 0 sales. Insiders bought $516,774 and sold $0 worth of stock, for net insider buying of $516,774. The most recent filing shows Higuchi John W. (Director) buying 15,970 shares at $2.23 on Sep 30, 2026.

Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put LPCN's ownership changes in context.

Summary generated from market data by MetaCap's automated system. Methodology

LPCN insider transactions

Lipocine insider transactions
DateInsiderTypeSharesValueFiling
Sep 30, 2026Higuchi John W.DirectorBuy15,970$35.61KForm 4
Sep 29, 2026Higuchi John W.DirectorBuy9,037$19.43KForm 4
Sep 28, 2026Higuchi John W.DirectorBuy12,561$27.13KForm 4
Apr 7, 2026Higuchi John W.DirectorBuy40,000$81.20KForm 4
Apr 6, 2026Higuchi John W.DirectorBuy123,000$252.15KForm 4
Apr 6, 2026Patel Mahesh V.Chief Executive OfficerBuy25,000$50.75KForm 4
Apr 2, 2026Patel Mahesh V.Chief Executive OfficerBuy25,000$50.50KForm 4
Mar 8, 2024Fogarty KristaPrincipal Accounting OfficerAward991—Form 4
Mar 8, 2024Patel Mahesh V.CEO and PresidentAward4,893—Form 4
May 25, 2023Patel Mahesh V.CEO and PresidentBuy8,706$43.79KForm 4
Mar 24, 2023Patel Mahesh V.CEO and PresidentBuy150,000$48.00KForm 4
Mar 20, 2023Ono Richard DanaDirectorBuy4,000$1.36KForm 4
Mar 17, 2023Patel Mahesh V.CEO and PresidentBuy50,000$16.50KForm 4

Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4

Related